VEGFA and neoplasm: Several factors are important in this step, including the appropriate match between the tumor‐secreted chemokines and receptors expressed in T‐cells, the presence of an aberrant vasculature, and interactions between TCRs and adhesion molecules on endothelial cells (EC).[22] Bevacizumab, an antibody that blocks the vascular endothelial growth factor (VEGF) secreted by tumors, is a promising candidate to enhance the infiltration of lymphocytes by promoting “vascular normalization” and EC activation (Table 2).[23, 24]